Literature DB >> 9339669

Evaluation of dementia: a systematic study of the usefulness of the American Academy of Neurology's practice parameters.

H Chui1, Q Zhang.   

Abstract

OBJECTIVE: This study examined the usefulness of the "Practice Parameters for the Evaluation of Dementia," published by the Quality Standards Subcommittee of the American Academy of Neurology (1994). The Practice Parameters are stratified according to three levels of certainty (standards, guidelines, and options), and suggest indications for the use of neuroimaging studies.
METHODS: We reviewed 119 consecutive cases referred for assessment of memory loss to a university-affiliated interdisciplinary clinic. We assessed the diagnostic value of laboratory, neuropsychological, and neuroimaging studies above the standard history, neurologic, and mental status examinations. We also assessed the sensitivity and specificity of four clinical indicators (i.e., early symptom onset, noninsidious course, focal neurologic signs or symptoms, and gait disturbance) for predicting the diagnostic utility of neuroimaging studies.
RESULTS: The largest changes in diagnostic categories between the standard and the comprehensive diagnostic process was a 9% decrease in the diagnosis of Alzheimer's disease, a 6% increase in the diagnosis of mixed dementia (due largely to laboratory studies), and a 4% increase in the diagnosis of vascular dementia (due to neuroimaging). The clinical indicators were 82% sensitive and 50% specific in predicting that neuroimaging studies would change the diagnosis. In six cases, meaningful neuroimaging findings were not associated with any clinical indicator (5% false negatives). In 43 cases, neuroimaging provided no significant clinical findings despite the presence of an indicator (36% false positives).
CONCLUSIONS: In this convenience sample, diagnostic accuracy was improved to a comparable degree by laboratory and neuroimaging studies, although at a significant difference in cost. Use of the four clinical indicators would have reduced the frequency of neuroimaging studies by 33% but missed clinically meaningful information in 5%. Although imperfect, the Practice Parameters represent a first step toward improving the cost effectiveness of the dementia work-up.

Entities:  

Mesh:

Year:  1997        PMID: 9339669     DOI: 10.1212/wnl.49.4.925

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  8 in total

1.  Alone in the home.

Authors:  Roy Yaari; Geri R Hall; Helle Brand; James D Seward; Anna D Burke; Adam S Fleisher; Jan Dougherty; Pierre N Tariot
Journal:  Prim Care Companion CNS Disord       Date:  2012-02-23

2.  The impact of MRI combined with visual rating scales on the clinical diagnosis of dementia: a prospective study.

Authors:  Martijn V Verhagen; Gerard L Guit; Gerrit Jan Hafkamp; Kees Kalisvaart
Journal:  Eur Radiol       Date:  2015-08-29       Impact factor: 5.315

Review 3.  Is there a future for cyclo-oxygenase inhibitors in Alzheimer's disease?

Authors:  Lap Ho; Weiping Qin; Breton S Stetka; Giulio M Pasinetti
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

4.  Radial width of the temporal horn: a sensitive measure in Alzheimer disease.

Authors:  Giovanni B Frisoni; Cristina Geroldi; Alberto Beltramello; Angelo Bianchetti; Giuliano Binetti; Giovanni Bordiga; Charles DeCarli; Mikko P Laakso; Hilkka Soininen; Cristina Testa; Orazio Zanetti; Marco Trabucchi
Journal:  AJNR Am J Neuroradiol       Date:  2002-01       Impact factor: 3.825

Review 5.  The appropriate use of neuroimaging in the diagnostic work-up of dementia: an economic literature review and cost-effectiveness analysis.

Authors:  S L Bermingham
Journal:  Ont Health Technol Assess Ser       Date:  2014-02-01

Review 6.  The appropriate use of neuroimaging in the diagnostic work-up of dementia: an evidence-based analysis.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2014-02-01

Review 7.  Alzheimer Disease.

Authors:  Liana G Apostolova
Journal:  Continuum (Minneap Minn)       Date:  2016-04

Review 8.  Brain SPECT as a Biomarker of Neurodegeneration in Dementia in the Era of Molecular Imaging: Still a Valid Option?

Authors:  Rodolfo Ferrando; Andres Damian
Journal:  Front Neurol       Date:  2021-05-10       Impact factor: 4.003

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.